Tirzepatide for Type 2 Diabetes

Questions for Deliberation and Voting: January 20th Public Meeting
These questions are intended for the deliberation of the New England CEPAC voting body at the public meeting.

Patient Population for all questions: Adults with type 2 diabetes with inadequate glycemic control despite ongoing background antihyperglycemic agent(s).

Clinical Evidence

1. Is the currently available evidence adequate to demonstrate that the net health benefit of tirzepatide added to background therapy is superior to that provided by background therapy alone?

   Yes       No

2. Is the currently available evidence adequate to demonstrate that the net health benefit of tirzepatide added to background therapy is superior to that of adding injectable semaglutide (Ozempic®) to background therapy?

   Yes       No

3. Is the currently available evidence adequate to demonstrate that the net health benefit of tirzepatide added to background therapy is superior to that of adding empagliflozin (Jardiance®) to background therapy?

   Yes       No
Contextual Considerations and Potential Other Benefits or Disadvantages

Please vote on the following contextual considerations:

When making judgments of overall long-term value for money, what is the relative priority that should be given to any effective treatment for type 2 diabetes on the basis of the following contextual considerations:

1= Very low priority; 2 = Low priority; 3 = Average priority; 4 = High priority; 5= Very high priority

4. Acuity of need for treatment of individual patients based on short-term risk of death or progression to permanent disability
5. Magnitude of the lifetime impact on individual patients of the condition being treated

Please vote on the following potential other benefits or disadvantages:

What are the relative effects of tirzepatide added to background therapy versus injectable semaglutide (Ozempic®) added to background therapy on the following outcomes that inform judgment of the overall long-term value for money of tirzepatide?

1= Major negative effect; 2 = Minor negative effect; 3 = No difference; 4 = Minor positive effect; 5 = Major positive effect

6. Patients’ ability to achieve major life goals related to education, work, or family life
7. Caregivers’ quality of life and/or ability to achieve major life goals related to education, work, or family life
8. Society’s goal of reducing health inequities

Long-term Value for Money

At the time of the evidence report publishing (January 6, 2022), the level of support around the assumed tirzepatide placeholder price was not strong enough to take a tirzepatide long-term value for money vote.